Table 4.
Time-to-onset analysis for signals with strong/moderate/weak prioritization.
| Prioritization | Weibull distribution | Failure type | ||||||
|---|---|---|---|---|---|---|---|---|
| Cases | TTO (days) | Scale parameter | Shape parameter | |||||
| n | Median (IQR) | Min–max | α | 95% CI | β | 95% CI | ||
| Strong | 125 | 23 (2–92) | 0–833 | 33.45 | 21.07–53.11 | 0.40 | 0.34–0.46 | Early failure |
| Moderate | 2,138 | 6 (0–31) | 0–717 | 8.07 | 7.35–8.85 | 0.34 | 0.33–0.35 | Early failure |
| Weak | 229 | 7 (0–32.25) | 0–688 | 10.11 | 6.79–15.05 | 0.33 | 0.30–0.37 | Early failure |
n, number of cases with available time-to-onset; IQR, interquartile range; TTO, Time-to-onset. When TTO is 0 days, the adverse event occurred within the same day with the therapy.